Merck MRK, known as MSD outside the United States and Canada, today
announced that its New Drug Application for an investigational, tablet
formulation of the company's antifungal agent, NOXAFIL^® (posaconazole), has
been accepted for review by the U.S. Food and Drug Administration (FDA).
Merck currently markets NOXAFIL Oral Suspension for prophylaxis of invasive
Aspergillus and Candida infections in patients 13 years of age and older who
are at high risk of developing these infections due to being severely
immunocompromised, such as patients who have received hematopoietic stem cell
transplants and have graft-versus-host disease, or patients with cancers of
the blood who are experiencing prolonged low white blood cell counts
(neutropenia) as a result of chemotherapy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in